Randomized trial published on JAMA Internal Medicine confirms Ivermectin is ineffective against progression to Severe COVID
Ivermectin treatment given to high-risk patients with mild-to-moderate COVID-19 during the first week of illness did not prevent progression to severe disease, according to results from a randomized clinical trial. “The study findings do not support the use of ivermectin for patients with COVID-19,” researchers conclude in the paper published online today in JAMA Internal Medicine. The open-label